Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn's disease.
about
Proof-of-concept, randomized, controlled clinical trial of Bacillus-Calmette-Guerin for treatment of long-term type 1 diabetesSelective death of autoreactive T cells in human diabetes by TNF or TNF receptor 2 agonismAnti-inflammatory therapy by ibudilast, a phosphodiesterase inhibitor, in demyelination of twitcher, a genetic demyelination modelA comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumabMultiple sclerosis and inflammatory bowel diseases: what we know and what we would need to know!Optic neuritis associated with adalimumab in the treatment of uveitis.Extraintestinal manifestations and complications in inflammatory bowel diseases.Neurological disorders and inflammatory bowel diseasesAdverse events in IBD: to stop or continue immune suppressant and biologic treatmentA practical approach to monitoring patients on biological agents for the treatment of psoriasisIdiopathic inflammatory demyelinating disease of the central nervous system in patients with inflammatory bowel disease: retrospective analysis of 9095 patientsInfliximab in the treatment of Crohn's disease.Optic neuritis occurring with anti-tumour necrosis factor alpha therapy.A case report of adalimumab-associated optic neuritis.A role for transcription factor NF-kappaB in autoimmunity: possible interactions of genes, sex, and the immune response.Neurologic manifestations of ulcerative colitis.Recent advances in the medical therapy of Crohn's disease in childhood.Optic Neuritis Associated or Not with TNF Antagonists in Patients with Inflammatory Bowel Disease.Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease.A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease.Occurrence of demyelinating diseases after anti-TNFα treatment of inflammatory bowel disease: A Danish Crohn Colitis Database study.Concomitant rheumatoid arthritis and amyotrophic lateral sclerosis: report of two new cases and review of literature.Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors.Biological therapies for inflammatory bowel disease: controversies and future options.Demyelination during tumour necrosis factor antagonist therapy for psoriasis: a case report and review of the literature.Inflammatory bowel disease and demyelination: more than just a coincidence?Neurologic manifestations of gastrointestinal and liver diseases.Adverse Events During Anti-TNFα Therapies in IBD (Excluding Infections and Malignancies): When to Stop, Continue, or Switch Therapies.Cogan's Syndrome in Patients With Inflammatory Bowel Disease--A Case Series.Neurologic Manifestations of Inflammatory Bowel Disease.Central nervous system demyelination associated with etanercept in a 51 years old woman.Demyelinizing Neurological Disease after Treatment with Tumor Necrosis Factor-α Antagonists.Fatal aseptic meningoencephalitis following infliximab treatment for inflammatory bowel diseasePractical guidelines for the treatment of inflammatory bowel disease.
P2860
Q21134119-B3FF317A-0F47-4C71-A3EE-79F3847744C8Q24652453-9CCB7182-33DC-4011-82E1-A7D3580B4BFDQ24804031-60A40364-E92F-439E-8A62-47752F37604FQ28282330-7083344C-28CD-4F6F-95BA-5BE1F5CF4017Q30571620-2DB841E4-5289-4290-83AE-2FAB28CB7F4FQ33681462-27C9EF1B-5C72-4D0D-84CD-476C47C04363Q33866998-AA149744-BE02-436B-A418-043D9BA4D1FDQ33958822-2F65B3E6-883C-469C-929D-2C1A35443BEDQ34073191-4F200D96-7D7A-47C3-AF6E-B5F3F1ADEFE3Q34156420-4BB4D312-44F0-408C-8A3A-B9CF9F9761EFQ35811221-C58DD06D-1785-4387-BE01-1D1AC23CD96FQ35919228-B2421B85-89C2-4465-9910-154D834EDB4EQ35954593-31B16E19-6B18-4EF8-8817-EBE6DF493C42Q36223187-76D219D8-672B-446E-ABF0-06C2F7773FDEQ36654727-913FE61E-D49B-45DB-88A5-BFC5E47D3E44Q36793208-5774971B-0B72-4E88-95BB-1A5A238C6BD8Q36968175-92BFCA2E-18F1-4EAC-8889-6EA91C3230ECQ37118403-1954F46A-0709-4A8E-BE74-87311DE2B991Q37223169-030B907D-8FE5-4B85-88B3-0DC49C5C5171Q37814549-A4AED02E-7037-40AD-84F4-558D5D518958Q37822506-8C8A8B21-C1F5-42B1-AB58-FAC3543F8049Q37831814-C577CF8A-2B14-4123-AE24-6232ADBD2242Q37911726-A6FFD65B-8E2E-4D64-9B9E-5DF4DC31B321Q37960183-51113CB7-3CC4-4028-AF90-5A51431DB70AQ37977994-EEA157EB-E8BA-45D8-813E-93D36AF95227Q38184633-137C40D1-0CE3-49F2-85AE-81390105A216Q38244670-E7B187D6-48DC-42A5-8666-9DC642C3251DQ38751610-7501F0B7-CF7B-4302-9B9F-0E6BE4C1B401Q40721929-BDD949A4-A211-4C3B-B93A-675058268C8DQ41530993-BE3CB74B-1053-4EBD-A5A0-D894DC14D427Q41826013-84B6E519-C7F4-4699-A785-E55E7BE83ADDQ41934387-626FF2E8-F63C-4747-85DC-9D1B1448E56EQ42844422-6207926C-8EC0-417D-90DE-191D2F963C85Q42846582-AE035987-F7BA-47F8-A3A8-3474437C32FB
P2860
Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn's disease.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Demyelination during anti-tumo ...... nfliximab for Crohn's disease.
@en
Demyelination during anti-tumo ...... nfliximab for Crohn's disease.
@nl
type
label
Demyelination during anti-tumo ...... nfliximab for Crohn's disease.
@en
Demyelination during anti-tumo ...... nfliximab for Crohn's disease.
@nl
prefLabel
Demyelination during anti-tumo ...... nfliximab for Crohn's disease.
@en
Demyelination during anti-tumo ...... nfliximab for Crohn's disease.
@nl
P2860
P1476
Demyelination during anti-tumo ...... nfliximab for Crohn's disease.
@en
P2093
Brian G Weinshenker
Carlton W Thomas
P2860
P356
10.1097/00054725-200401000-00004
P577
2004-01-01T00:00:00Z